ArticleBiomedical signal processing and control2017
Prostate cancer recognition based on mass spectrometry sensing data and data fingerprint recovery.
Article in Biomedical signal processing and control, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The high dimensionality and noisy spectra of Mass Spectrometry (MS) data are two of the main challenges to achieving high accuracy recognition. The objective of this work is to produce an accurate prediction of class content by employing compressive sensing (CS). Not only can CS significantly reduce MS data dimensionality, but it will also allow for full reconstruction of original data. We are proposing a weighted mixing of L1- and L2-norms via a regularization term as a classifier within compressive sensing framework. Using performance measures such as OSR, PPV, NPV, Sen and Spec, we show that the L2-algorithm with regularization terms outperforms the L1-algorithm and Q5 under all applicable assumptions. We also aimed to use Block Sparse Bayesian Learning (BSBL) to reconstruct the MS data fingerprint which has also shown better performance results that those of L1-norm. These techniques were successfully applied to MS data to determine patient risk of prostate cancer by tracking Prostate-specific antigen (PSA) protein, and this analysis resulted in better performance when compared to currently used algorithms such as L1 minimization. This proposed work will be particularly useful in MS data reduction for assessing disease risk in patients and in future personalized medicine applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.